News
NTRB
6.29
+1.45%
0.09
Weekly Report: what happened at NTRB last week (0310-0314)?
Weekly Report · 16h ago
Weekly Report: what happened at NTRB last week (0303-0307)?
Weekly Report · 03/10 12:10
Weekly Report: what happened at NTRB last week (0224-0228)?
Weekly Report · 03/03 12:09
Nutriband Inc. Reports Financial Results for the Quarter Ended October 31, 2024
Press release · 03/03 11:16
Weekly Report: what happened at NTRB last week (0217-0221)?
Weekly Report · 02/24 12:09
Nutriband receives Certificate of Registration from USPTO for trademark
TipRanks · 02/21 12:16
Nutriband Receives Certificate of Registration for Trademark covering Pharmaceutical and Product Research and Development.
Barchart · 02/21 06:00
Weekly Report: what happened at NTRB last week (0210-0214)?
Weekly Report · 02/17 12:05
Noble Financial Sticks to Its Buy Rating for Nutriband (NTRB)
TipRanks · 02/14 14:25
Nutriband Expands Partnership with Kindeva for Aversa™
TipRanks · 02/13 17:25
NUTRIBAND AND KINDEVA DRUG DELIVERY FORMALIZE EXCLUSIVE DEVELOPMENT PARTNERSHIP FOR AVERSA™ FENTANYL ABUSE DETERRENT FENTANYL PATCH
Reuters · 02/13 12:20
Nutriband, Kindeva Drug Delivery formalize exclusive development partnership
TipRanks · 02/13 12:10
Nutriband Secures USPTO Notice for Aversa™ Technology
TipRanks · 02/12 21:32
Nutriband appoints Anastasia Nichita to advisory board
TipRanks · 02/11 14:10
NUTRIBAND INC. ANNOUNCES OLYMPIAN ANASTASIA NICHITA TO ADVISORY BOARD
Reuters · 02/11 14:00
Biotech Alert: Searches spiking for these stocks today
TipRanks · 02/10 16:25
Weekly Report: what happened at NTRB last week (0203-0207)?
Weekly Report · 02/10 11:57
Nutriband receives notice of allowance for new U.S. Patent for its transdermal abuse deterrent technology; shares rise
Seeking Alpha · 02/07 13:57
Nutriband receives notice of allowance for U.S. patent covering Aversa tech
TipRanks · 02/07 13:52
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga · 02/07 12:05
More
Webull provides a variety of real-time NTRB stock news. You can receive the latest news about Nutriband Inc through multiple platforms. This information may help you make smarter investment decisions.
About NTRB
More
Nutriband Inc. is engaged in the development of a portfolio of transdermal pharmaceutical products. Its development pipeline consists of transdermal products that are based on proprietary AVERSA abuse-deterrent transdermal technology. Its lead product under development is AVERSA Fentanyl, an abuse deterrent fentanyl transdermal system that combines an approved generic fentanyl patch with its AVERSA abuse deterrent transdermal technology to reduce the abuse and misuse of fentanyl patches. Its development pipeline also includes AVERSA Buprenorphine and AVERSA Methylphenidate. It is developing a portfolio of transdermal pharmaceutical products to deliver already approved drugs or biologics that are typically delivered by injection but with the potential to improve compliance and therapeutic outcomes through transdermal delivery. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.